Resource Center

Frequently Asked Questions

Operational Skills

Training Salon

All Categories >

Return to Overview

Pharmaceutical Source Workshop, Session 2 | Antibody Discovery and Drug-likeness Analysis

 

Part 01

Course Content Arrangement

1

May 13:

Antibody Discovery: The First Step in Developing Novel Antibody Therapeutics

08:30–10:00 Overview of the Antibody Discovery Platform

10:00–10:30 Tea Break

10:30–12:00 Development and Applications of Phage Display Technology

12:00–13:30 Lunch and rest

13:30–15:00 Development and Application of Antibody Display on the Surface of Mammalian Cells

15:00–15:30 Tea Break

15:30–17:00 Discussion of Case Studies on Technology-Based Antibody Screening

 

2

May 14:

Evaluation of Antibody Drug Developability and Drug-likeness:

Bridge Between Antibody Discovery and CMC

08:30–10:00 Overview of the Domestic and International Markets and Development of Antibody Drugs

10:00–10:30 Tea Break

10:30–12:00 Antibody Sequence Analysis

12:00–13:30 Lunch and rest

13:30–15:00 Physicochemical Analysis and Stability Assessment of Antibody Proteins

15:00–15:15 Tea Break

15:30–16:45 Feasibility of CMC Development for Antibody Drugs

 

 

 

Part 02

Guest Biography

Dr. Zhou Chen

Founder of Shuangzhan Bio

Founder, Chairman, and General Manager of Takamori (Shanghai) Biotechnology Co., Ltd.

Specializes in the screening of fully human monoclonal antibodies and the research and development of novel antibody therapeutics. Graduated from the First Military Medical University of Guangzhou and subsequently earned master’s and doctoral degrees from the Fourth Military Medical University of Xi’an (now the Air Force Medical University). In 1987, he went to the University of Southern California in the United States for postdoctoral studies and as a visiting scholar. He has held positions as a researcher at Immusol and Amgen in California, as well as deputy general manager, chief scientist, and general manager at several domestic biotechnology companies, and as a visiting or distinguished professor at Southern Medical University. His work focuses on the research and development of biologic macromolecular drugs; he has led or participated in the development of four biologics that have successively entered clinical trials, one of which is a Class 1 innovative antibody drug in China. Since 2002, he has been dedicated to the R&D of antibody library display technologies, having filed two international patent applications—on phage antibody library construction and on cell-surface full-length antibody display screening. He possesses unique insights and extensive hands-on experience in areas such as the construction of fully human antibody libraries, humanization of antibodies, the screening of high-expression, high-affinity antibodies, and the establishment of screening platforms. The seamless integration of phage display and cell-based display for monoclonal antibody screening that he has developed is internationally leading and uniquely proprietary in China.

 

Dr. Lin Jun

Ascentage Bio

Vice President of Molecular Evaluation and Development

With more than 15 years of experience in the development of macromolecular protein therapeutics, he has led or participated in the submission of domestic and international IND applications for over 20 monoclonal antibody, bispecific antibody, ADC, and HPV vaccine projects, as well as the NDA filing for three monoclonal antibody programs. He possesses extensive expertise across the entire product lifecycle, including new drug research and development and evaluation, IND program development, and the industrialization and commercialization of NDA-approved products. He has successively undertaken or contributed to projects such as the 863 Program, the 973 Program, the National Major New Drug Creation Program, and the Pudong New Area Science and Technology Development Fund Innovation Fund, and has published 10 SCI/EI articles and filed/obtained 6 domestic and international patents.

 

 

 

 

 

TAG:

Previous:

Themed Salon | Antibody Discovery: The First Step in Developing Novel Antibody Drugs

Next:

No!